Teva's Pipeline Pivot: Can Duvakitug Transform the Generics Giant?
As Teva Pharmaceutical shifts focus from its legacy generics business to a promising innovative pipeline, its experimental drug Duvakitug emerges as a potential valuation catalyst. We examine the bull case, the competitive landscape, and what it means for investors.